Equity Sector Funds Very High Risk
The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies
Expert-managed portfolios tailored to your financial goals.
Estimation is based on the past performance
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | 5.58% | 6.09% | 0.67% | -3.68% | 4.04% | 9.84% | 22.1% | 15.82% | 13.33% | 14.48% | 19.73% |
| Category returns | 6.83% | 7.45% | 0.03% | -2.3% | 6.38% | 11.92% | 22.96% | 16.06% | 13.74% | 12.95% | N/A |
| Absolute returns | 8.25% | 7.39% | 5.52% | 4.6% | 9.85% | 25.79% | 94.6% | 100.85% | 90.6% | 286.63% | 5363.39% |
| Rank within category | 16 | 15 | 6 | 13 | 14 | 9 | 6 | 5 | 7 | 1 | N/A |
| Total Schemes in Category | 18 | 18 | 17 | 17 | 16 | 14 | 10 | 10 | 9 | 4 | N/A |
| Sector Funds | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Yearly returns | -10.58% | 7.61% | 3.64% | 1.68% | 66.44% | 23.93% | -9.9% | 39.15% | 34.04% | -3.34% | 7.23% |
| Q1 returns | -12.47% | 0.87% | -7.37% | 1.47% | -5.7% | -1.15% | -7.5% | -4.25% | 9.06% | -8.69% | -3.88% |
| Q2 returns | 2.17% | -4.95% | 6.95% | -6.5% | 31.59% | 22.06% | -10.12% | 17.1% | 4.01% | 7.82% | 11.56% |
| Q3 Returns | 7.77% | 0.19% | 10.7% | -1.11% | 19.5% | 0.73% | 8.2% | 11.23% | 17.22% | -4.42% | N/A |
| Q4 Returns | -7.22% | 12.03% | -5.5% | 8.38% | 12.24% | 1.97% | 0.15% | 11.58% | 0.8% | 2.72% | N/A |
Expense ratio: 1.52%
Inclusive of GST
Exit load
1% on or before 1M, Nil after 1M
| Alpha | -0.0548562 |
| Beta | 0.9167 |
| Sharpe Ratio | 0.332894 |
| Sortino Ratio | 0.740301 |
| R-Squared | 0.9302 |
| Tracking Error | 1.1011 |
| Downside Risk | 15.5842 |
| Std. Deviation (Annualised) | 13.9321 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Expense Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth | 9.18% | 6.67% | -0.99% | -3.59% | 7.1% | 27.02% | 16.23% | 0% | 19.44% | 6,293.14 | 1.87 | 0.39 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | 7.91% | 7.54% | 0.1% | -2.35% | 8.33% | 24.87% | 13.99% | 12.81% | 14.66% | 1,055.53 | 2.28 | 0.35 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | 5.71% | 8.21% | 0.45% | -1.13% | 4.56% | 24.83% | 15.56% | 12.3% | 16.26% | 4,063.64 | 1.93 | 0.37 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | 6.15% | 10.25% | 3.03% | 0.11% | 9.4% | 23.81% | 14.41% | 0% | 19.42% | 2,753.72 | 1.94 | 0.34 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | 4.7% | 6.4% | 1.22% | -1.71% | 5.37% | 22.75% | 12.57% | 0% | 18.41% | 858.87 | 2.30 | 0.33 | Very High |
| Nippon India Pharma Fund - Growth Current | 5.58% | 6.09% | 0.67% | -3.68% | 4.04% | 22.1% | 13.33% | 14.48% | 19.73% | 7,898.24 | 1.82 | 0.32 | Very High |
| Tata India Pharma & Healthcare Fund - Regular Plan - Growth | 6.85% | 5.21% | -3.15% | -4.34% | 2.3% | 22.03% | 13.39% | 12.21% | 11.21% | 1,229.42 | 2.15 | 0.30 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | 8.21% | 4.38% | -0.83% | -4.8% | 4.87% | 21.77% | 13.64% | 0% | 20.1% | 2,891.76 | 1.94 | 0.31 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | 7.33% | 7.14% | -1.96% | -3.4% | 4.69% | 20.94% | 10.57% | 0% | 16.19% | 78.30 | 2.36 | 0.29 | Very High |
| ITI Pharma & Healthcare Fund - Regular Plan - Growth | 8.1% | 8.47% | -2.98% | -5.82% | 0.32% | 19.48% | 0% | 0% | 10.95% | 211.30 | 2.35 | 0.25 | Very High |
| Instrument Allocation | Instrument | Assets % |
|---|---|---|
|
|
Domestic Equities | 98.68% |
| Cash & Cash Equivalents and Net Assets | 1.32% |
| Sector Allocation | Sector | Assets % |
|---|---|---|
| Pharmaceuticals & Biotechnology | 73.57% | |
| Healthcare Services | 21.33% | |
| Retailing | 3.78% | |
| Others | 1.32% |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 13.85% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.95% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.04% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.61% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.47% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 5.01% |
| Medplus Health Services Ltd. | Retailing | Domestic Equities | 3.78% |
| Vijaya Diagnostic Centre Ltd. | Healthcare Services | Domestic Equities | 3.36% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.27% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.19% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 3.16% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.04% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.83% |
| Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.55% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.50% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.26% |
| Thyrocare Technologies Ltd. | Healthcare Services | Domestic Equities | 2.11% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.09% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 1.99% |
| Pfizer Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.79% |
| Narayana Hrudayalaya Ltd. | Healthcare Services | Domestic Equities | 1.74% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.68% |
| Emcure Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.50% |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 1.43% |
| Suraksha Diagnostic Ltd. | Healthcare Services | Domestic Equities | 1.32% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 1.22% |
| Sanofi Consumer Healthcare India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.22% |
| Akums Drugs & Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.99% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.96% |
| Sanofi India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.94% |
| Triparty Repo | Cash & Cash Equivalents and Net Assets | 0.86% | |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.63% |
| Astrazeneca Pharma India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.61% |
| Indoco Remedies Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.46% |
| Net Current Assets | Cash & Cash Equivalents and Net Assets | 0.45% | |
| Concord Biotech Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.15% |
| Cash Margin - CCIL | Cash & Cash Equivalents and Net Assets | 0.01% | |
| Total | 100.00% |
RETURNS
It is an Open ended scheme that primarily invests in Sector Funds.
The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies
The scheme benchmark is the BSE Health Care - TRI
It is classified as Very High Risk, suitable for investors with a Very High risk appetite.
Returns Delivered by the funds are as follows:
1-year: 9.85%
3-year: 24.82%
5-year: 13.76%
Top holdings include names such as:
The NAV is around ₹546.34 (approx.) for the Nippon India Pharma Fund - Growth.
The fund’s AUM is approximately ₹8,365 Cr.
The expense ratio for the Regular Plan is 1.52.
1% on or before 1M, Nil after 1M.
Minimum SIP starts at ₹1000.
The minimum lump sum investment is ₹5000. Often platforms may require higher in practice, but the statutory minimum remains the same.
You can start a SIP through:
Broker/agent platform like Sharescart.
Enter KYC details, choose the Regular Growth option, set SIP amount/frequency, and submit.
Yes. You can modify your SIP amount or frequency anytime online through the Sharescart platform.
You can redeem online via the Sharescart platform — choose the scheme, select the amount/units, and submit. Proceeds are credited to your bank account.
The fund manager: Sailesh Raj Bhan
This fund is suitable for investors with a Very High risk tolerance.
Get personalized Portfolio Management Services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
